Skip to main content
Skip to section navigation
Skip to footer
About
Our Mission
Leadership
Board of Directors
Approach
Pipeline
Overview
Congenital Hyperinsulinism
Tumor Hyperinsulinism
Diabetic Macular Edema
Publications
Publications
Data Presentations
For Patients
Join Us
Values
Benefits
Open Positions
Investors & Media
Overview
Corporate Presentation
News
Events
Stock Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Governance
Info
Contact Us
SEC Filings
Investors
Investors
Overview
Corporate Presentation
News
Events
Stock Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Governance
Info
Filing Type
View All
10-K
10-K/A
10-Q
10-Q/A
3
3/A
4
4/A
424B3
424B5
8-A12B
8-A12B/A
8-A12G
8-K
8-K/A
8-K12B
CERT
CORRESP
CT ORDER
D
D/A
DEF 14A
DEF 14C
DEFA14A
EFFECT
NT 10-K
NT 10-Q
POS AM
PRE 14A
PRE 14C
PRER14A
PRER14C
RW
S-1
S-1/A
S-3
S-3/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC 14F1
SC TO-I
SC TO-I/A
UPLOAD
Year
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
SEC Filings
Date
Form
Description
XBRL
Pages
04/30/18
3
Form 3: Initial statement of beneficial ownership of securities
2
04/30/18
SC 13G
Form SC 13G: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
5
04/24/18
D/A
Form D/A: Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
7
04/09/18
8-K
Form 8-K: Current report filing
8
04/04/18
8-K
Form 8-K: Current report filing
5
04/03/18
8-K
Form 8-K: Current report filing
23
03/28/18
SC 13D
Form SC 13D: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
8
03/15/18
CT ORDER
Form CT ORDER: Confidential treatment order
1
02/15/18
D
Form D: Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
7
02/15/18
424B3
Form 424B3: Prospectus filed pursuant to Rule 424(b)(3)
39
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
Page
29
Page
30
Page
31
Page
32
Page
33
Page
34
Page
35
Page
36
Page
37
Page
38
…
Page
62
Next Page
arrow_forward
Select a page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Stay Connected
email
Email Alerts
contact_page
Contacts
rss_feed
RSS News Feed
MENU
About
Leadership
Board of Directors
Scientific Advisory Board
Approach
Overview
Congenital Hyperinsulinism
Tumor Hyperinsulinism
Additional Programs
Pipeline
Overview
Congenital Hyperinsulinism
Tumor Hyperinsulinism
Additional Programs
Publications
Publications
Data Presentations
For Patients
Join Us
Values
Benefits
Open Positions
Investors & Media
Overview
Corporate Presentation
News
Events
Stock Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Governance
Info
Contact Us